One hundred forty patients with ES-SCLC were randomized to chemotherapy alone (cisplatin and etoposide) or rh-endostatin plus chemotherapy for four to six cycles, followed by single-agent rh-endostatin until progression or unacceptable toxicity. This evidence concerns the gene COL18A1 and small cell lung carcinoma.